Previous 10 | Next 10 |
Vericel (NASDAQ:VCEL) is scheduled to announce Q4 earnings results on Wednesday, February 24th, before market open.The consensus EPS Estimate is $0.20 (flat Y/Y) and the consensus Revenue Estimate is $45M (+14.2% Y/Y).Over the last 2 years, VCEL has beaten EPS estimates 75% of the time and ha...
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the SVB Leerink 10 ...
CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the B...
CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that its Board of Directors unanimously approved the termination of the Company’s shareholder ri...
CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter 2020 financial results and busi...
Vericel ([[VCEL]] +1.4%) has appointed Joe Mara as Chief Financial Officer of the Company, effective today.He brings over 20 years of experience, including more than 14 years of experience in the biotech industry. Most recently, Mr. Mara served as Vice President, Finance and Head of Investor ...
CAMBRIDGE, Mass., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, announced the appointment of Joe Mara as Chief Financial Officer of the Company, effective today. Mr. Mara joins ...
Oppenheimer has stepped away from its buy-equivalent rating on Vericel ([[VCEL]] -5.2%) after the company released preliminary fourth-quarter results. The stock has been downgraded to perform from outperform.Q4 sales for MACI a membrane used to repair cartilage is expected to be $34.4M-$34.9M...
Record Quarterly and Full-Year Total Revenues Fourth Quarter Revenue Growth of Approximately 15% CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, toda...
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 23 rd Annua...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, w...
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2024 financial results on Thursday, August 1, 2024. Vericel’s m...
2024-07-08 00:00:04 ET Ryan Zimmerman from BTIG issued a price target of $56.00 for VCEL on 2024-07-05 10:09:00. The adjusted price target was set to $56.00. At the time of the announcement, VCEL was trading at $46.68. The overall price target consensus is at $48.00 with...